Australia markets closed

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.2500+0.0400 (+1.25%)
At close: 04:00PM EDT
3.4000 +0.15 (+4.62%)
After hours: 07:21PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 15.94M
Enterprise value -6.29M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.96
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.50

Trading information

Stock price history

Beta (5Y monthly) -0.46
52-week change 3-32.29%
S&P500 52-week change 323.10%
52-week high 36.7500
52-week low 32.8880
50-day moving average 34.3724
200-day moving average 33.9955

Share statistics

Avg vol (3-month) 3246.17k
Avg vol (10-day) 323.3k
Shares outstanding 54.91M
Implied shares outstanding 64.91M
Float 84.71M
% held by insiders 161.66%
% held by institutions 11.37%
Shares short (15 Apr 2024) 451.85k
Short ratio (15 Apr 2024) 41.39
Short % of float (15 Apr 2024) 42.50%
Short % of shares outstanding (15 Apr 2024) 41.06%
Shares short (prior month 15 Mar 2024) 468.43k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 331 Dec 2019
Ex-dividend date 4N/A
Last split factor 21:8
Last split date 321 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-35.26%
Return on equity (ttm)-64.89%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -15.88M
Net income avi to common (ttm)-12.47M
Diluted EPS (ttm)-2.4600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)22.43M
Total cash per share (mrq)4.57
Total debt (mrq)203k
Total debt/equity (mrq)1.22%
Current ratio (mrq)3.78
Book value per share (mrq)3.40

Cash flow statement

Operating cash flow (ttm)-10.8M
Levered free cash flow (ttm)-15.55M